Healthcare

A risks of myocardial infarction and cardiac death risk could linked and increased level of uric acid in the blood (hyperuricemia) of the patients patients with metabolic syndrome.

This suggestion just reported in the American Journal of Cardiology in the October 26, 2010.

According to the authors of the study, this relationship might stem from the effect of hyperuricemia on adverse cardiac outcomes, or from a synergistic interaction of hyperuricemia with other metabolic syndrome components, or from involvement of hyperuricemia in a long-term inflammatory process.

The senior author of the study, Dr. Pierre Chouraqui from Tel Aviv University and colleagues noted that patient with metabolic syndrome have high serum uric acid levels, but it has not been clear if hyperuricemia is an active component of metabolic syndrome or a secondary phenomenon.

This findings based on their evaluation to determine possible relationship between hyperuricemia and adverse outcomes in 2963 patients who enrolled in a study of the Bezafibrate Infacrtion Prevention.

The primary endpoint of the study was the first occurrence of an acute myocardial infarction or sudden cardiac death, and according to the results, the metabolic syndrome patients with hyperuricemia had a significant 45% higher incidence of that primary endpoint, even after adjustment for numerous factors.

According to investigators, there was a similar pattern in subjects without metabolic syndrome. They said that compared with patients with normal uric acid levels, patients with high uric acid levels had higher total cholesterol and triglyceride levels, and lower HDL cholesterol and estimated glomerular filtration rates.

However, for the hyperuricemia patients without metabolic syndrome, the increased of incidence of the primary endpoint was not statistically significant (36%).

They note, “Normouricemic patients with metabolic syndrome demonstrated a similar outcome as hyperuricemia patients without metabolic syndrome. Thus, our results suggest that hyperuricemia not only is a frequent finding but also appears to be a marker of adverse cardiac outcome allowing further risk stratification of patients with metabolic syndrome.”